- Conditions
- Dry Eye Disease
- Interventions
- OC-01 (varenicline) nasal spray, Placebo (vehicle control) nasal spray
- Drug
- Lead sponsor
- Oyster Point Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Long Term Follow up Dry Eye Disease
- Interventions
- OC-01 Low Dose, 0.12 mg/mL, OC-01 Mid Dose, 0.6 mg/mL, OC-01 High Dose, 1.2 mg/mL, Placebo (vehicle) nasal spray
- Drug
- Lead sponsor
- Oyster Point Pharma, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Newport Beach, California • Indianapolis, Indiana • Andover, Massachusetts
- Conditions
- Dry Eye Disease
- Interventions
- OC-01 (varenicline) nasal spray, Placebo (vehicle) nasal spray
- Drug
- Lead sponsor
- Oyster Point Pharma, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 3
- States / cities
- Newport Beach, California • Indianapolis, Indiana • Andover, Massachusetts
- Conditions
- Neurotrophic Keratopathy
- Interventions
- OC-01 (varenicline) nasal spray 1.2 mg/ml, Placebo (vehicle) nasal spray
- Drug
- Lead sponsor
- Oyster Point Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 31
- States / cities
- Dothan, Alabama • Irvine, California • Los Angeles, California + 27 more
- Conditions
- Dry Eye Disease (DED)
- Interventions
- OC-01 (varenicline) nasal spray, Placebo (vehicle) nasal spray
- Drug
- Lead sponsor
- Oyster Point Pharma, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 758 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Newport Beach, California • Fort Collins, Colorado + 18 more